Smith Jason Drew's Form 4/A amendment
AmendedUroGen Pharma Ltd. (URGN) · filed Feb 5, 2024
- Accession no.
- 0001437749-24-003155
- Filed
- Feb 5, 2024
- Trade date
- Feb 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Feb 2, 2024
This filing lists 3 non-derivative transactions. It carries over 10 transactions from the original filing that it did not restate. Open-market sales total $157.4K. It was filed 4 days after the trade.
This amendment restates part of 0001437749-24-003018 (filed Feb 2, 2024). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smith Jason DrewCIK 0001821479 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Ordinary Shares | SSaleDisposed | −417 | $15.78F2 | −$6,580.26 | 18,824 | Direct | |
| Feb 1, 2024 | Ordinary Shares | SSaleDisposed | −1,248 | $15.78F2 | −$19,693.44 | 20,076 | Direct | |
| Feb 1, 2024 | Ordinary Shares | SSaleDisposed | −3,328 | $15.78F2 | −$52,515.84 | 23,414 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001437749-24-003018 (filed Feb 2, 2024).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Ordinary Shares | MOption exerciseAcquired | +834 | –F1 | – | 19,241 | Direct | |
| Jan 31, 2024 | Ordinary Shares | SSaleDisposed | −417 | $15.74 | −$6,563.58 | 18,824 | Direct | |
| Jan 31, 2024 | Ordinary Shares | MOption exerciseAcquired | +2,500 | –F1 | – | 21,324 | Direct | |
| Jan 31, 2024 | Ordinary Shares | SSaleDisposed | −1,248 | $15.74 | −$19,643.52 | 20,076 | Direct | |
| Jan 31, 2024 | Ordinary Shares | MOption exerciseAcquired | +6,666 | –F1 | – | 26,742 | Direct | |
| Jan 31, 2024 | Ordinary Shares | SSaleDisposed | −3,328 | $15.74 | −$52,382.72 | 23,414 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Ordinary Shares | MOption exerciseDisposed | −834 | $0.00 | $0 | 0 | Direct | |
| Jan 31, 2024 | Ordinary Shares | MOption exerciseDisposed | −2,500 | $0.00 | $0 | 2,500 | Direct | |
| Jan 31, 2024 | Ordinary Shares | MOption exerciseDisposed | −6,666 | $0.00 | $0 | 13,334 | Direct | |
| Jan 31, 2024 | Ordinary Shares | AGrant or awardAcquired | +16,500 | $0.00 | $0 | 16,500 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
Referenced by the price of 3 transactions in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024.
- F2
This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024.
Referenced by the price of 3 transactions in Table I.